beta

ADXS

Advaxis, Inc.

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

Actual EPS
Consensus EPS
Estimated EPS
Number of Estimates
EPS Surprise

Stats

Summary

Advaxis, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of proprietary Lm-based antigen delivery products. These immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm) bioengineered to secrete antigen/adjuvant fusion proteins. These Lm-based strains are believed to be a significant advancement in immunotherapy as they integrate multiple functions into a single immunotherapy and are designed to access and direct antigen presenting cells to stimulate anti-tumor T cell immunity, activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment to enable T cells to eliminate tumors.

Market Cap: 50.2 Million

Primary Exchange: NASDAQ

Website: www.advaxis.com

Shares Outstanding: 146 Million

Float: 0

Dividend: 0.0 (0.0%)

Beta: 1.23411395545527

Sector: Manufacturing

Industry: Pharmaceutical Preparation Manufacturing

Ethical Flags

Longest drawdown: 1774 trading days

From: 2015-06-01 To: 2021-12-01

Lowest Point:

Advaxis, Inc. (ADXS) CEO Kenneth Berlin on Q2 2019 Results - Earnings Call Transcript

via: SeekingAlpha at 2019-06-11 10:53:04:000

Advaxis, Inc. (ADXS) Q2 2019 Earnings Conference Call June 11, 2019 11:00 A.M. ET Company Participants Yvonne Briggs - Vice President, LHA Kenneth Berlin - President and Chief Executive Officer Andres Gutierrez - Executive Vice President and Chief Medical Officer Molly Henderso… read more...

Advaxis, Inc. (ADXS) CEO Kenneth Berlin on Q2 2019 Results - Earnings Call Transcript

via: SeekingAlpha at 2019-06-11 10:53:04:000

Advaxis, Inc. (ADXS) Q2 2019 Earnings Conference Call June 11, 2019 11:00 A.M. ET Company Participants Yvonne Briggs - Vice President, LHA Kenneth Berlin - President and Chief Executive Officer Andres Gutierrez - Executive Vice President and Chief Medical Officer Molly Henderso… read more...

Advaxis, Inc. (ADXS) CEO Kenneth Berlin on Q2 2019 Results - Earnings Call Transcript

via: SeekingAlpha at 2019-06-11 10:53:04:000

Advaxis, Inc. (ADXS) Q2 2019 Earnings Conference Call June 11, 2019 11:00 A.M. ET Company Participants Yvonne Briggs - Vice President, LHA Kenneth Berlin - President and Chief Executive Officer Andres Gutierrez - Executive Vice President and Chief Medical Officer Molly Henderso… read more...

Caseys General Stores among after hour gainers

via: SeekingAlpha at 2019-06-10 13:38:05:000

Gainers: NBY +20.3% . CASY +9.4% . KEG +3.5% . CHAP +3.2% . CXW +2.7% . More news on: NovaBay Pharmaceuticals, Inc., Casey's General Stores, Inc., Key Energy Services, Inc., Stocks on the move, , News on ETFs Read more … read more...

Advaxis  EPS misses by $0.02, beats on revenue

via: SeekingAlpha at 2019-06-10 12:08:10:000

Advaxis (NASDAQ: ADXS ): Q2 GAAP EPS of -$1.59 misses by $0.02 . More news on: Advaxis, Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news, , Read more … read more...

Advaxis Reports Second Quarter Fiscal 2019 Financial Results and Provides Pipeline Update

via: Business Wire at 2019-06-10 12:05:00:000

Conference call to be held June 11 at 11:00 a.m. ET Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced an update on its clinical pipeline and financial results … read more...

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
Data provided by IEX Cloud